Browsing by Author "de Vries G."

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    Aligning the good practice mask with the objectives of the European innovation partnership on active and healthy ageing
    (Korean Academy of Asthma, Allergy and Clinical Immunology, 2020) Bousquet J.; Farrell J.; Onorato G.L.; Bedbrook A.; Czarlewski W.; Micheli Y.; Arnavielhe S.; Illario M.; Ansotegui I.J.; Anto J.M.; Bachert C.; Basagaña X.; Bédard A.; Benveniste S.; Bergmann K.C.; Bewick M.; Bindslev-Jensen C.; Bjermer L.; Blain H.; Bosnic-Anticevich S.; Bosse I.; Braido F.; Brussino L.; Camuzat T.; Canonica G.W.; Cardona V.; Carreiro Martins P.; Cecchi L.; Chavannes N.H.; Chu D.K.; Correia da Sousa J.; Costa D.J.; Costa E.; Cruz A.A.; da Silva J.; Devillier P.; de Feo G.; de Vries G.; Dray G.; Ebisawa M.; Erhola M.; Fauquert J.L.; Fokkens W.J.; Fonseca J.; Fontaine J.M.; Gemicioğlu B.; Haahtela T.; Heffler E.; Hellings P.W.; Ivancevich J.C.; Jassem E.; Jutel M.; Kaidashev I.; Kalayci O.; Klimek L.; Kowalski M.L.; Kull I.; Kuna P.; Kvedariene V.; la Grutta S.; Laune D.; Larenas-Linnemann D.; Ierodiakonou D.; Le L.T.T.; Lourenço O.; Makris M.; Menditto E.; Monti R.; Morais-Almeida M.; Münter L.; Muraro A.; Murray R.; Maurer M.; Melén E.; Mösges R.; Mullol J.; Niedoszytko M.; O'Hehir R.E.; Okamoto Y.; Papadopoulos N.G.; Passalacqua G.; Patella V.; Pereira A.M.; Pfaar O.; Pham-Thi N.; Portejoie F.; Price D.; Prokopakis E.P.; Psarros F.; Raciborski F.; Regateiro F.; Reitsma S.; Roche N.; Rolland C.; Ryan D.; Samolinski B.; Sastre J.; Scadding G.K.; Schmid-Grendelmeier P.; Schünemann H.J.; Shamji M.; Sheikh A.; Stellato C.; Suppli-Ulrik C.; Somekh D.; Sova M.; Todo Bom A.; Tomazic P.V.; Toppila-Salmi S.; Triggiani M.; Tsiligianni I.; Valero A.; Valiulis A.; Valovirta E.; van Eerd M.; Vasankari T.; Ventura M.T.; Wallace D.; Waserman S.; Yorgancioglu A.; Zidarn M.; Zuberbier T.
    The reference sites of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) were renewed in 2019. The DG Santé good practice Mobile Airways Sentinel networK was reviewed to meet the objectives of the EIP on AHA. It included 1) Management of care process, 2) Blueprint of digital transformation, 3) EIP on AHA, innovation to market, 4) Community for monitoring and assessment framework, 5) Political, organizational, technological and financial readiness, 6) Contributing to European co-operation and transferability, 7) Delivering evidence of impact against the triple win approach, 8) Contribution to the European Digital Transformation of Health and Care and 9) scale of demonstration and deployment of innovation. © 2020 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https:// creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • No Thumbnail Available
    Item
    Validity, reliability, and responsiveness of daily monitoring visual analog scales in MASK-air®
    (John Wiley and Sons Inc, 2021) Sousa-Pinto B.; Eklund P.; Pfaar O.; Klimek L.; Zuberbier T.; Czarlewski W.; Bédard A.; Bindslev-Jensen C.; Bedbrook A.; Bosnic-Anticevich S.; Brussino L.; Cardona V.; Cruz A.A.; de Vries G.; Devillier P.; Fokkens W.J.; Fuentes-Pérez J.M.; Gemicioğlu B.; Haahtela T.; Huerta-Villalobos Y.R.; Ivancevich J.C.; Kull I.; Kuna P.; Kvedariene V.; Larenas Linnemann D.E.; Laune D.; Makris M.; Melén E.; Morais-Almeida M.; Mösges R.; Mullol J.; O'Hehir R.E.; Papadopoulos N.G.; Pereira A.M.; Prokopakis E.P.; Psarros F.; Regateiro F.S.; Reitsma S.; Samolinski B.; Scichilone N.; da Silva J.; Stellato C.; Todo-Bom A.; Tomazic P.V.; Salmi S.T.; Valero A.; Valiulis A.; Valovirta E.; van Eerd M.; Ventura M.T.; Yorgancioglu A.; Basagaña X.; Antó J.M.; Bousquet J.; Fonseca J.A.
    Background: MASK-air® is an app that supports allergic rhinitis patients in disease control. Users register daily allergy symptoms and their impact on activities using visual analog scales (VASs). We aimed to assess the concurrent validity, reliability, and responsiveness of these daily VASs. Methods: Daily monitoring VAS data were assessed in MASK-air® users with allergic rhinitis. Concurrent validity was assessed by correlating daily VAS values with those of the EuroQol-5 Dimensions (EQ-5D) VAS, the Control of Allergic Rhinitis and Asthma Test (CARAT) score, and the Work Productivity and Activity Impairment Allergic Specific (WPAI-AS) Questionnaire (work and activity impairment scores). Intra-rater reliability was assessed in users providing multiple daily VASs within the same day. Test–retest reliability was tested in clinically stable users, as defined by the EQ-5D VAS, CARAT, or “VAS Work” (i.e., VAS assessing the impact of allergy on work). Responsiveness was determined in users with two consecutive measurements of EQ-5D-VAS or “VAS Work” indicating clinical change. Results: A total of 17,780 MASK-air® users, with 317,176 VAS days, were assessed. Concurrent validity was moderate–high (Spearman correlation coefficient range: 0.437–0.716). Intra-rater reliability intraclass correlation coefficients (ICCs) ranged between 0.870 (VAS assessing global allergy symptoms) and 0.937 (VAS assessing allergy symptoms on sleep). Test–retest reliability ICCs ranged between 0.604 and 0.878—“VAS Work” and “VAS asthma” presented the highest ICCs. Moderate/large responsiveness effect sizes were observed—the sleep VAS was associated with lower responsiveness, while the global allergy symptoms VAS demonstrated higher responsiveness. Conclusion: In MASK-air®, daily monitoring VASs have high intra-rater reliability and moderate–high validity, reliability, and responsiveness, pointing to a reliable measure of symptom loads. © 2021 The Authors. Clinical and Translational Allergy published by John Wiley and Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
  • No Thumbnail Available
    Item
    UCRAID (Ukrainian Citizen and refugee electronic support in Respiratory diseases, Allergy, Immunology and Dermatology) action plan
    (John Wiley and Sons Inc, 2023) Bousquet J.; Samolinski B.; Kaidashev I.; Maurer M.; Roche N.; Sousa-Pinto B.; Kurchenko A.; Stepanenko R.; Tsaryk V.; Klimek L.; Ventura M.T.; Bedbrook A.; Czarlewski W.; Lysanets Y.; Kupczyk M.; Skolimowski Ł.; Kulus M.; Del Giacco S.; Ollert M.; Garcia-Aymerich J.; Robalo Cordeiro C.; Yorgancioglu A.; Schlapbach C.; Amaral R.; Bonaglia C.; Bossé I.; Buquicchio R.; Christou D.; Fedoruk G.; Fontanesi P.; Gemicioglu B.; Giuliano A.F.M.; Lepore P.; Nakonechna A.; Neisinger S.; Pereira A.M.; Ramanauskaite A.; Raciborski F.; Sitkauskiene B.; Sokhatska O.; Stepanenko V.; Stevanovic K.; Syzon O.; Kvedariene V.; de Vries G.; van Eerd M.; Valiulis A.; Fonseca J.A.; Anto J.M.; Haahtela T.; Schünemann H.; Zuberbier T.
    Eight million Ukrainians have taken refuge in the European Union. Many have asthma and/or allergic rhinitis and/or urticaria, and around 100,000 may have a severe disease. Cultural and language barriers are a major obstacle to appropriate management. Two widely available mHealth apps, MASK-air® (Mobile Airways Sentinel NetworK) for the management of rhinitis and asthma and CRUSE® (Chronic Urticaria Self Evaluation) for patients with chronic spontaneous urticaria, were updated to include Ukrainian versions that make the documented information available to treating physicians in their own language. The Ukrainian patients fill in the questionnaires and daily symptom-medication scores for asthma, rhinitis (MASK-air) or urticaria (CRUSE) in Ukrainian. Then, following the GDPR, patients grant their physician access to the app by scanning a QR code displayed on the physician's computer enabling the physician to read the app contents in his/her own language. This service is available freely. It takes less than a minute to show patient data to the physician in the physician's web browser. UCRAID—developed by ARIA (Allergic Rhinitis and its Impact on Asthma) and UCARE (Urticaria Centers of Reference and Excellence)—is under the auspices of the Ukraine Ministry of Health as well as European (European Academy of Allergy and Clinical immunology, EAACI, European Respiratory Society, ERS, European Society of Dermatologic Research, ESDR) and national societies. © 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
  • No Thumbnail Available
    Item
    Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence–Assisted ARIA Care Pathways (ARIA 2024)
    (American Academy of Allergy, Asthma and Immunology, 2024) Bousquet J.; Schünemann H.J.; Sousa-Pinto B.; Zuberbier T.; Togias A.; Samolinski B.; Bedbrook A.; Czarlewski W.; Hofmann-Apitius M.; Litynska J.; Vieira R.J.; Anto J.M.; Fonseca J.A.; Brozek J.; Bognanni A.; Brussino L.; Canonica G.W.; Cherrez-Ojeda I.; Cruz A.A.; Vecillas L.D.L.; Dykewicz M.; Gemicioglu B.; Giovannini M.; Haahtela T.; Jacobs M.; Jacomelli C.; Klimek L.; Kvedariene V.; Larenas-Linnemann D.E.; Louis G.; Lourenço O.; Leemann L.; Morais-Almeida M.; Neves A.L.; Nadeau K.C.; Nowak A.; Palamarchuk Y.; Palkonen S.; Papadopoulos N.G.; Parmelli E.; Pereira A.M.; Pfaar O.; Regateiro F.S.; Savouré M.; Taborda-Barata L.; Toppila-Salmi S.K.; Torres M.J.; Valiulis A.; Ventura M.T.; Williams S.; Yepes-Nuñez J.J.; Yorgancioglu A.; Zhang L.; Zuberbier J.; Abdul Latiff A.H.; Abdullah B.; Agache I.; Al-Ahmad M.; Al-Nesf M.A.; Al Shaikh N.A.; Amaral R.; Ansotegui I.J.; Asllani J.; Balotro-Torres M.C.; Bergmann K.-C.; Bernstein J.A.; Bindslev-Jensen C.; Blaiss M.S.; Bonaglia C.; Bonini M.; Bossé I.; Braido F.; Caballero-Fonseca F.; Camargos P.; Carreiro-Martins P.; Casale T.; Castillo-Vizuete J.-A.; Cecchi L.; Teixeira M.D.C.; Chang Y.-S.; Loureiro C.C.; Christoff G.; Ciprandi G.; Cirule I.; Correia-de-Sousa J.; Costa E.M.; Cvetkovski B.; de Vries G.; Del Giacco S.; Devillier P.; Dokic D.; Douagui H.; Durham S.R.; Enecilla M.L.; Fiocchi A.; Fokkens W.J.; Fontaine J.-F.; Gawlik R.; Gereda J.E.; Gil-Mata S.; Giuliano A.F.M.; Gotua M.; Gradauskiene B.; Guzman M.A.; Hossny E.; Hrubiško M.; Iinuma T.; Irani C.; Ispayeva Z.; Ivancevich J.C.; Jartti T.; Jeseňák M.; Julge K.; Jutel M.; Kaidashev I.; Bennoor K.S.; Khaltaev N.; Kirenga B.; Kraxner H.; Kull I.; Kulus M.; Kuna P.; Kupczyk M.; Kurchenko A.; La Grutta S.; Lane S.; Miculinic N.; Lee S.M.; Le Thi Tuyet L.; Lkhagvaa B.; Louis R.; Mahboub B.; Makela M.; Makris M.; Maurer M.; Melén E.; Milenkovic B.; Mohammad Y.; Moniuszko M.; Montefort S.; Moreira A.; Moreno P.; Mullol J.; Nadif R.; Nakonechna A.; Navarro-Locsin C.G.; Neffen H.E.; Nekam K.; Niedoszytko M.; Nunes E.; Nyembue D.; O'Hehir R.; Ollert M.; Ohta K.; Okamoto Y.; Okubo K.; Olze H.; Padukudru M.A.; Palomares O.; Pali-Schöll I.; Panzner P.; Palosuo K.; Park H.S.; Passalacqua G.; Patella V.; Pawankar R.; Pétré B.; Pitsios C.; Plavec D.; Popov T.A.; Puggioni F.; Quirce S.; Raciborski F.; Ramonaité A.; Recto M.; Repka-Ramirez S.; Roberts G.; Robles-Velasco K.; Roche N.; Rodriguez-Gonzalez M.; Romualdez J.A.; Rottem M.; Rouadi P.W.; Salapatas M.; Sastre J.; Serpa F.S.; Sayah Z.; Scichilone N.; Senna G.; Sisul J.C.; Solé D.; Soto-Martinez M.E.; Sova M.; Sozinova O.; Stevanovic K.; Ulrik C.S.; Szylling A.; Tan F.M.; Tantilipikorn P.; Todo-Bom A.; Tomic-Spiric V.; Tsaryk V.; Tsiligianni I.; Urrutia-Pereira M.; Rostan M.V.; Sofiev M.; Valovirta E.; Van Eerd M.; Van Ganse E.; Vasankari T.; Vichyanond P.; Viegi G.; Wallace D.; Wang D.Y.; Waserman S.; Wong G.; Worm M.; Yusuf O.M.; Zaitoun F.; Zidarn M.
    The traditional healthcare model is focused on diseases (medicine and natural science) and does not acknowledge patients’ resources and abilities to be experts in their own lives based on their lived experiences. Improving healthcare safety, quality, and coordination, as well as quality of life, is an important aim in the care of patients with chronic conditions. Person-centered care needs to ensure that people's values and preferences guide clinical decisions. This paper reviews current knowledge to develop (1) digital care pathways for rhinitis and asthma multimorbidity and (2) digitally enabled, person-centered care.1 It combines all relevant research evidence, including the so-called real-world evidence, with the ultimate goal to develop digitally enabled, patient-centered care. The paper includes (1) Allergic Rhinitis and its Impact on Asthma (ARIA), a 2-decade journey, (2) Grading of Recommendations, Assessment, Development and Evaluation (GRADE), the evidence-based model of guidelines in airway diseases, (3) mHealth impact on airway diseases, (4) From guidelines to digital care pathways, (5) Embedding Planetary Health, (6) Novel classification of rhinitis and asthma, (7) Embedding real-life data with population-based studies, (8) The ARIA-EAACI (European Academy of Allergy and Clinical Immunology) strategy for the management of airway diseases using digital biomarkers, (9) Artificial intelligence, (10) The development of digitally enabled, ARIA person-centered care, and (11) The political agenda. The ultimate goal is to propose ARIA 2024 guidelines centered around the patient to make them more applicable and sustainable. © 2024 The Authors
  • No Thumbnail Available
    Item
    Adherence to Treatment in Allergic Rhinitis During the Pollen Season in Europe: A MASK-air Study
    (John Wiley and Sons Inc, 2025) Sousa-Pinto B.; Costa E.M.; Vieira R.J.; Klimek L.; Czarlewski W.; Pfaar O.; Bedbrook A.; Amaral R.; Brussino L.; Kvedariene V.; Larenas-Linnemann D.E.; Iinuma T.; Pham-Thi N.; Regateiro F.S.; Taborda-Barata L.; Ventura M.T.; Ansotegui I.J.; Bergmann K.C.; Canonica G.W.; Cardona V.; Cecchi L.; Cherrez-Ojeda I.; Cingi C.; Cruz A.A.; Del Giacco S.; Devillier P.; Fokkens W.J.; Gemicioglu B.; Haahtela T.; Ivancevich J.C.; Kuna P.; Kraxner H.; Laune D.; Louis R.; Makris M.; Morais-Almeida M.; Mösges R.; Niedoszytko M.; Papadopoulos N.G.; Patella V.; Pereira A.M.; Reitsma S.; Robles-Velasco K.; Rouadi P.W.; Samolinski B.; Sova M.; Toppila-Salmi S.K.; Sastre J.; Valiulis A.; Yorgancioglu A.; Zidarn M.; Zuberbier T.; Fonseca J.A.; Bousquet J.; Anto J.M.; Kupczyk M.; Kulus M.; Roche N.; Scichilone N.; Almeida R.; Bosnic-Anticevich S.; Braido F.; Loureiro C.C.; de Vries G.; Giuliano A.F.M.; Jácome C.; Kaidashev I.; Louis G.; Lourenço O.; Makela M.; Maurer M.; Mullol J.; Nadif R.; O’Hehir R.; Okamoto Y.; Ollert M.; Olze H.; Pétré B.; Puggioni F.; Romantowski J.; Rivero-Yeverino D.; Rodriguez-Gonzalez M.; Sá-Sousa A.; Savouré M.; Serpa F.S.; Shamji M.H.; Sheikh A.; Ulrik C.S.; Sofiev M.; Sperl A.; Todo-Bom A.; Tsiligianni I.; Valovirta E.; van Eerd M.; Blain H.; Boulet L.-P.; Brusselle G.; Buhl R.; Charpin D.; Casale T.; Chivato T.; Correia-de-Sousa J.; Corrigan C.; de Blay F.; Dykewicz M.; Fiocchi A.; Giovannini M.; Jassem E.; Jutel M.; Keil T.; La Grutta S.; Lipworth B.; Papi A.; Pépin J.-L.; Quirce S.; Cordeiro C.R.; Torres M.J.; Usmani O.S.; Bonini M.; Gradauskiene B.; Brightling C.
    Background: Adherence to rhinitis treatment has been insufficiently assessed. We aimed to use data from the MASK-air mHealth app to assess adherence to oral antihistamines (OAH), intra-nasal corticosteroids (INCS) or azelastine-fluticasone in patients with allergic rhinitis. Methods: We included regular European MASK-air users with self-reported allergic rhinitis and reporting at least 1 day of OAH, INCS or azelastine-fluticasone. We assessed weeks during which patients answered the MASK-air questionnaire on all days. We restricted our analyses to data provided between January and June, to encompass the pollen seasons across the different assessed countries. We analysed symptoms using visual analogue scales (VASs) and the combined symptom-medication score (CSMS), performing stratified analyses by weekly adherence levels. Medication adherence was computed as the proportion of days in which patients reported rhinitis medication use. Sensitivity analyses were performed considering all weeks with at most 1 day of missing data and all months with at most 4 days of missing data. Results: We assessed 8212 complete weeks (1361 users). Adherence (use of medication > 80% days) to specific drug classes ranged from 31.7% weeks for azelastine-fluticasone to 38.5% weeks for OAH. Similar adherence to rhinitis medication was found in users with or without self-reported asthma, except for INCS (better adherence in asthma patients). VAS and CSMS levels increased from no adherence to full adherence, except for INCS. A higher proportion of days with uncontrolled symptoms was observed in weeks with higher adherence. In full adherence weeks, 41.2% days reported rhinitis co-medication. The sensitivity analyses displayed similar results. Conclusions: A high adherence was found in patients reporting regular use of MASK-air. Different adherence patterns were found for INCS compared to OAH or azelastine-fluticasone that are likely to impact guidelines. © 2025 The Author(s). Clinical & Experimental Allergy published by John Wiley & Sons Ltd.